Instructions for use of Elotuzumab injection

Elotuzumab(Elotuzumab) is a monoclonal antibody drug used to treat multiple myeloma (MM) and is often used in combination with other drugs to enhance the therapeutic effect. Its mechanism of action is to promote the immune system to eliminate myeloma cells by targeting and activating natural killer (NK) cells. When using evolizumab, correct dosage and administration are critical to ensure the drug's efficacy and safety.

Evolizumab injection is often used in combination with Lenalidomide and Dexamethasone, especially during multiple cycles of treatment. The standard usage and dosage regimen is that patients receive 10 mg/kg of evolizumab intravenously every week for the first two cycles of treatment (one cycle of 28 days), and then the same dose is administered intravenously every two weeks in subsequent treatment cycles until disease progression or unacceptable toxicity. The purpose of this regimen is to strengthen the immune response through more frequent dosing in the early stages and then gradually reduce the dosing frequency to maintain efficacy.

In addition, evolizumab can also be used in combination with pomalidomide (Pomalidomide) and dexamethasone. Under this regimen, patients receive 10 mg/kg of evolizumab intravenously every week for the first two cycles and 20 mg/kg every four weeks starting in the third cycle until disease progression or unacceptable toxicity. With this treatment regimen, doctors hope to enhance the long-term effects of treatment, especially in patients who already have treatment resistance.

When using evolizumab, possible side effects also need to be prevented and managed. Before treatment, patients usually need to take drugs such as dexamethasone, diphenhydramine, ranitidine, and acetaminophen to reduce allergic reactions and other adverse reactions. Common side effects of evolizumab include fever, chills, headache, allergic reactions, etc. Therefore, close monitoring is required during medication, especially for patients with a history of allergies.

Reference materials:https://www.empliciti.com/